Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Johnson and Johnson
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cavosonstat

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Cavosonstat?

Cavosonstat is an investigational drug.

There have been 8 clinical trials for Cavosonstat. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2019.

The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Asthma. The leading clinical trial sponsors are Nivalis Therapeutics, Inc., University of North Carolina, Chapel Hill, and National Heart, Lung, and Blood Institute (NHLBI).

There are nine US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for Cavosonstat
TitleSponsorPhase
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyNational Heart, Lung, and Blood Institute (NHLBI)Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyUniversity of North Carolina, Chapel HillPhase 2
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)Nivalis Therapeutics, Inc.Phase 1

See all Cavosonstat clinical trials

Clinical Trial Summary for Cavosonstat

Top disease conditions for Cavosonstat
Top clinical trial sponsors for Cavosonstat

See all Cavosonstat clinical trials

US Patents for Cavosonstat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cavosonstat   Start Trial Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors N30 Pharmaceuticals, Inc. (Boulder, CO)   Start Trial
Cavosonstat   Start Trial Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors N30 Pharmaceuticals, Inc. (Boulder, CO)   Start Trial
Cavosonstat   Start Trial Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors Nivalis Therapeutics, Inc. (Boulder, CO)   Start Trial
Cavosonstat   Start Trial Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors Nivalis Therapeutics, Inc. (Boulder, CO)   Start Trial
Cavosonstat   Start Trial Substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors Nivalis Therapeutics, Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cavosonstat

Drugname Country Document Number Estimated Expiration Related US Patent
Cavosonstat Australia 2011343518 2030-12-16   Start Trial
Cavosonstat Brazil 112013014681 2030-12-16   Start Trial
Cavosonstat Canada 2821412 2030-12-16   Start Trial
Cavosonstat China 103328430 2030-12-16   Start Trial
Cavosonstat European Patent Office 2651223 2030-12-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Merck
Medtronic
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.